Immediate-release omeprazole + Delayed-release omeprazole

ApprovedCompleted

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Gastroparesis

Conditions

Gastroparesis, Gastroesophageal Reflux Disease

Trial Timeline

Jun 1, 2007 → Dec 1, 2008

NCT ID

NCT00492622

About Immediate-release omeprazole + Delayed-release omeprazole

Immediate-release omeprazole + Delayed-release omeprazole is a approved stage product being developed by Bausch Health for Gastroparesis. The current trial status is completed. This product is registered under clinical trial identifier NCT00492622. Target conditions include Gastroparesis, Gastroesophageal Reflux Disease.

What happened to similar drugs?

5 of 7 similar drugs in Gastroparesis were approved

Approved (5) Terminated (4) Active (2)

✅tadalafilEli LillyApproved

✅Mosapride + domperidoneSumitomo PharmaApproved

✅Cisapride + PlaceboJohnson & JohnsonApproved

✅TegaserodNovartisApproved

🔄TradipitantVanda PharmaceuticalsPhase 3

🔄Tradipitant + Placebo + Open Label TradipitantVanda PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00492622	Approved	Completed	Jun 1, 2007	Dec 1, 2008	Gastroparesis

Competing Products

19 competing products in Gastroparesis

See all competitors

Product	Company	Stage	Hype Score
tadalafil + tadalafil + placebo	Eli Lilly	Phase 2	35
Granisetron	Kyowa Kirin	Phase 2	27
tadalafil	Eli Lilly	Approved	35
Mosapride + domperidone	Sumitomo Pharma	Approved	39
Cisapride + Placebo	Johnson & Johnson	Approved	35
Cisapride + Placebo	Johnson & Johnson	Approved	35
Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet	AstraZeneca	Phase 2	27
Sitagliptin + Placebo	Merck	Phase 1	29
Tegaserod	Novartis	Approved	35
Reglan ODT	UCB	Pre-clinical	26
Hemin + Albumin	Recordati	Phase 2	32
CNSA-001 + Placebo	PTC Therapeutics	Phase 2	32
Velusetrag + Placebo	Theravance Biopharma	Phase 2	29
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo	Theravance Biopharma	Phase 2	29
IW-9179 + Matching Placebo	Ironwood Pharmaceuticals	Phase 2	29
VLY-686 (Tradipitant)	Vanda Pharmaceuticals	Phase 2	25
Tradipitant	Vanda Pharmaceuticals	Phase 3	37
Tradipitant	Vanda Pharmaceuticals	Pre-clinical	20
Tradipitant + Placebo + Open Label Tradipitant	Vanda Pharmaceuticals	Phase 3	30